AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2025
Mar 10, 2025
30604_dirs_2025-03-10_bb46e970-849f-4378-8376-b0f7ce04747f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-03-06
Reporting Person: Valantine Hannah (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-06 | Common Stock | M | 12875 | $16.75 | Acquired | 14639 | Direct |
| 2025-03-06 | Common Stock | S | 12875 | $32.5825 | Disposed | 1764 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-03-06 | Stock Option (right to buy) | $16.75 | M | 12875 | Disposed | 2033-06-21 | Common Stock (12875) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 3433 | Indirect |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024.
F2: Represents the weighted average sale price of the shares sold from $32.17 to $33.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: The stock option vests in three annual installments starting on June 21, 2024 and ending on June 21, 2026, subject to the Reporting Person's continued service on the Issuer's board of directors.